AN ANALYSIS OF THE GLOBAL IMMUNOGLOBULIN (IG) MARKET IN 2020
AND FORECAST TO THE YEAR 2027

As immunoglobulin (IG) is the dominant revenue-generating therapeutic protein from plasma fractionation, its future growth rate profoundly impacts the entire industry on a number of levels, including plasma requirements forecasting, plasma collection capacity planning, manufacturing infrastructure planning, projection of per-liter plasma valuation, and revenue and profit forecasting.  For these and other reasons, projection of the likely future demand for IG is of critical importance.

This new report takes a deep look at current IG usage levels around the globe, and details how IG is used by medical specialty and key indications across all five geographic regions (North America, South America, Asia/Pacific, Europe, and the Middle East/Africa).  MRB’s forecast model analyzes both key drivers of IG growth and risks to future growth, taking into account how the interaction of plasma supply and IG demand can be expected to influence price patterns globally over the next 7 years. This report identifies IG usage in over 80 countries in 2019 and 2020, including breakdowns of IVIG and SCIG market shares by geographic region.  For 2021 through 2027, the report forecasts country-level IG product sales in units, and regional sales in both U.S. dollars and average manufacturer-level price per gram.  Also detailed for each region are key growth drivers and expected growth rates by region over the forecast period. The COVID19 pandemic’s effect plasma collections and consequently the supply of IG is heavily discussed as it significantly effects the next few years of sales around the world.

Compared with a few years ago, there is increasing realization that new competition to IG usage in several autoimmune conditions including Myasthenia Gravis, ITP and CIDP is fast approaching. Of important concern among plasma fractionation companies, is the effect that new therapies will have on IG demand in these conditions.